Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

Timely treatment of GI symptoms leads to effective management of AS patients on NSAIDs

12 Feb 2020

Timely therapeutic strategies appear to effectively manage gastrointestinal (GI) risk in ankylosing spondylitis (AS) patients undergoing treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), as shown in a recent study.

The analysis involved 591 AS patients (mean age, 38.9 years; 82.1 percent male) treated with NSAIDs for at least 2 weeks. Researchers estimated GI risk using Standardized Calculator of Risk for Events (SCORE) and determined NSAID adherence using Morisky Medication Adherence Scale‐8 (MMAS‐8). Other outcomes investigated were disease activity and quality of life (QoL), assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and EuroQol‐3L (EQ‐5D, EQ‐visual analogue scale [EQ‐VAS]), respectively.

In the cohort, 196 patients (33.2 percent) reported a history of GI symptoms during NSAID treatment, and 64 of them (34.2 percent) had ongoing GI symptoms at baseline.

GI risk, according to the SCORE criteria, was moderate to very high in 37.1 percent of patients. None of the patients showed high adherence to NSAIDs, as shown by the MMAS‐8 scores. As a result, the 326 patients (55.3 percent) with moderate adherence were categorized as adherent and included for further analysis.

Mean BASDAI score was 3.5, and about 40 percent of the population showed suboptimal disease control. Mean QoL scores were 0.6 on EQ‐5D and 67.4 on EQ‐VAS. Path analyses revealed higher GI risk to be associated with significantly reduced QoL.

In light of the present data, GI risk should be monitored and considered as one of the key factors in improving QoL in AS patients on NSAIDs, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
3 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.